1. In silico drug repurposing in COVID-19. A network-based analysis
- Author
-
Simone Bini, Federica Conte, Lorenzo Farina, Giulia Fiscon, Marialuisa Sponziello, Paola Paci, Giuseppe Danilo Norata, Antonella Verrienti, Cosimo Durante, Valeria Pecce, Pasquale Sibilio, and Rosa Falcone
- Subjects
medicine.medical_specialty ,COVID-19 ,drug repurposing ,corticosteroid ,heparin ,inflammatory bowel diseases ,septic shock ,Coronavirus disease 2019 (COVID-19) ,In silico ,Anti-Inflammatory Agents ,RM1-950 ,Article ,Inflammatory bowel disease ,Pandemic ,medicine ,Humans ,Immunologic Factors ,Computer Simulation ,Enzyme Inhibitors ,Intensive care medicine ,Voltage-Gated Sodium Channel Blockers ,Pharmacology ,Drug discovery ,business.industry ,Gene Expression Profiling ,Drug Repositioning ,Healthy subjects ,General Medicine ,COVID-19 Drug Treatment ,Clinical trial ,Vaccination ,Drug repositioning ,Treatment Outcome ,Therapeutics. Pharmacology ,business ,Central Nervous System Agents - Abstract
The SARS-CoV-2 pandemic is a worldwide public health emergency. Despite the beginning of a vaccination campaign, the search for new drugs to appropriately treat COVID-19 patients remains a priority. Drug repurposing represents a faster and cheaper method than de novo drug discovery. In this study, we examined three different network-based approaches to identify potentially repurposable drugs to treat COVID-19. We analyzed transcriptomic data from whole blood cells of patients with COVID-19 and 21 other related conditions, as compared with those of healthy subjects. In addition to conventionally used drugs (e.g., anticoagulants, antihistaminics, anti-TNFα antibodies, corticosteroids), unconventional candidate compounds, such as SCN5A inhibitors and drugs active in the central nervous system, were identified. Clinical judgment and validation through clinical trials are always mandatory before use of the identified drugs in a clinical setting., Graphical Abstract ga1
- Published
- 2021
- Full Text
- View/download PDF